Cumulative evidence shows that the blood-based biomarker sNfL can predict relapses in relapsing MS patients, whereas CSF IgM oligoclonal bands, CHI3L1, and GFAP seem to be associated with a more progressive phenotype. The gene discussed is GFAP; the disease is myeloid sarcoma.